These results are in agreement with previous findings that PBX3 was significantly upregulated in FLT3-ITD+ compared to WT FLT3, karyotypically normal AML patient samples (Cauchy et al., 2015). The gene discussed is FLT3; the disease is acute myeloid leukemia.